Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents

Add time:08/07/2019    Source:sciencedirect.com

Human kinesin Eg5 is a potential inhibiting site for cancer chemotherapy. Blocking metaphase by binding foreign inhibitors with Eg5 eventually leads to apoptotic cell death. Here, we report the pyrazolopyrimidine derivates as potent inhibitors of Eg5 that prevents mitotic kinesin progression. IC50 values were evaluated against the motor domain of Eg5 using steady-state ATPase assay. To better understanding, we have performed molecular docking simulation. It reveals that the interactions of the proposed inhibitors with both the allosteric sites (helices α2, α3 and loopL5, and helices α4 & α6). Out of fifteen pyrazolopyrimidine derivates, three compounds (12, 25, and 27) have shown significant inhibition of Eg5. The synthesized compounds (12, 25, and 27) were tested for their in-vitro anticancer activity against cervical cancer cell line (HeLa).

We also recommend Trading Suppliers and Manufacturers of 4-AMINO-6-METHOXY-1H-PYRAZOLO[3,4-D]PYRIMIDINE (cas 100605-51-4). Pls Click Website Link as below: cas 100605-51-4 suppliers

Prev:Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers
Next:‘Gelozymes’ in organic synthesis. (Part 3): Lipase mediated synthesis of enantiomerically pure (R)- and (S)-enantiomers of 2-acetoxy-4-phenyl-(E)-but-3-enenitrile)